The suspected mechanism is that chemoradiotherapy-induced immune reactions leads to tumor CD274 (PD-L1) upregulation, which will be accessibly targeted by PD-1/PD-L1 immunotherapy31,32. This evidence concerns the gene CD274 and neoplasm.